Benzinga

España
Italia
대한민국
日本
Français
Benzinga Edge
Benzinga Research
Benzinga Pro

  • Get Benzinga Pro
  • Data & APIs
  • Events
  • Premarket
  • Advertise
Contribute
España
Italia
대한민국
日本
Français

Benzinga

  • Premium Services
  • Financial News
    Latest
    Earnings
    Guidance
    Dividends
    M&A
    Buybacks
    Interviews
    Management
    Offerings
    IPOs
    Insider Trades
    Biotech/FDA
    Politics
    Healthcare
    Small-Cap
  • Markets
    Pre-Market
    After Hours
    Movers
    ETFs
    Options
    Cryptocurrency
    Commodities
    Bonds
    Futures
    Mining
    Real Estate
    Volatility
  • Ratings
    Analyst Color
    Downgrades
    Upgrades
    Initiations
    Price Target
  • Investing Ideas
    Trade Ideas
    Long Ideas
    Short Ideas
    Technicals
    Analyst Ratings
    Analyst Color
    Latest Rumors
    Whisper Index
    Stock of the Day
    Best Stocks & ETFs
    Best Penny Stocks
    Best S&P 500 ETFs
    Best Swing Trade Stocks
    Best Blue Chip Stocks
    Best High-Volume Penny Stocks
    Best Small Cap ETFs
    Best Stocks to Day Trade
    Best REITs
  • Money
    Investing
    Cryptocurrency
    Mortgage
    Insurance
    Yield
    Personal Finance
    Forex
    Startup Investing
    Real Estate Investing
    Prop Trading
    Credit Cards
    Stock Brokers
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
Unusual Options Activity Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Screeners
Stock Screener
Top Momentum Stocks
Top Quality Stocks
Top Value Stocks
Top Growth Stocks
Compare Best Stocks
Best Momentum Stocks
Best Quality Stocks
Best Value Stocks
Best Growth Stocks
Connect With Us
facebookinstagramlinkedintwitteryoutubeblueskymastodon
About Benzinga
  • About Us
  • Careers
  • Advertise
  • Contact Us
Market Resources
  • Advanced Stock Screener Tools
  • Options Trading Chain Analysis
  • Comprehensive Earnings Calendar
  • Dividend Investor Calendar and Alerts
  • Economic Calendar and Market Events
  • IPO Calendar and New Listings
  • Market Outlook and Analysis
  • Wall Street Analyst Ratings and Targets
Trading Tools & Education
  • Benzinga Pro Trading Platform
  • Options Trading Strategies and News
  • Stock Market Trading Ideas and Analysis
  • Technical Analysis Charts and Indicators
  • Fundamental Analysis and Valuation
  • Day Trading Guides and Strategies
  • Live Investors Events
  • Pre market Stock Analysis and News
  • Cryptocurrency Market Analysis and News
Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

  • Terms & Conditions
  • Do Not Sell My Personal Data/Privacy Policy
  • Disclaimer
  • Service Status
  • Sitemap
© 2026 Benzinga | All Rights Reserved
January 11, 2022 11:14 PM 2 min read

Bill Gates Says Misinformation Related To Fauci, Himself Doesn't 'Make Sense,' Talks COVID-19 After Omicron

by Shivdeep Dhaliwal Benzinga Editor
Follow

ArticleFeaturedTickersList12345!!!

Microsoft Corporation (NASDAQ:MSFT) co-founder Bill Gates answered questions related to COVID-19 on Twitter Tuesday.

What Happened: The questions to Gates were routed through Devi Sridhar, director of Global Health Governance and a professor at the University of Edinburgh Medical School.

Gates said while the current vaccines prevent severe disease and death very well, they still allow breakthrough infections and their efficacy duration appears to be limited. 

“We need vaccines that prevent re-infection and have many years of duration.”

The former Microsoft executive addressed online misinformation — particularly that related to him and the Chief Medical Advisor to the President of United States Anthony Fauci — in the Twitter exchange with Sridhar.

 

On the progress of the COVID-19 pandemic through 2022, Gates struck a somewhat optimistic note.

See Also: How To Buy Microsoft (MSFT) Shares

Why It Matters: Gates is the co-chair of The Bill & Melinda Gates Foundation, which has committed more than $1.9 billion to support the global response to COVID-19.

In the early days of the COVID-19 pandemic, the Gates Foundation backed vaccine makers such as Inovio Pharmaceuticals Inc (NASDAQ:INO) and others.

Several conspiracy theories have emerged around Gates last year as the pandemic gripped the world, which he said were “almost hard to deny” because ‘it’s so stupid,” reported Business Insider.

Price Action: On Tuesday, Microsoft shares closed 0.2% higher at $314.98 in the regular session.

Read Next: Bill Gates To Oust Ex-Wife Melinda From Couples' Foundation If Divorced Pair Finds They Can't Get Along

Photo: Courtesy of Kuhlmann via Wikimedia

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.


Posted In:
NewsPenny StocksSmall CapAnthony FauciBill GatesCoronavirusCovid-19OmicronPandemic
MSFT Logo
MSFTMicrosoft Corp
$409.66-1.09%
Overview
INO Logo
INOInovio Pharmaceuticals Inc
$1.680.60%
MSFT Logo
MSFTMicrosoft Corp
$409.66-1.09%
Overview
INO Logo
INOInovio Pharmaceuticals Inc
$1.680.60%
Comments
Loading...